Comparison of the short-term efficacy of percutaneous endoscopic transforaminal lumbar interbody fusion with the application of a expandable versus PEEK cage for the treatment of lumbar degenerative disease - Takeaways - MDSpire
Coming Soon: Introducing MDSpire News. Learn more
Conexiant’s news site is now MDSpire News. Learn more

Short-Term Outcomes of Percutaneous Endoscopic Transforaminal Lumbar Interbody Fusion Using Expandable Versus PEEK Cages for Lumbar Degenerative Disease

  • By

  • Hao Han

  • Qi Lu

  • Yu Kong

  • Yiming Li

  • Weiqing Kong

  • Jie Li

  • Long Yang

  • Guangchao Cao

  • October 8, 2026

Share

  • 1

    This retrospective study compared short-term clinical and radiological outcomes of expandable and static PEEK cages in percutaneous endoscopic transforaminal lumbar interbody fusion.

  • 2

    Eligible patients had symptomatic lumbar degenerative disease despite 3 months of systematic conservative treatment and imaging findings consistent with their symptoms.

  • 3

    Patients with severe osteoporosis, severe lumbar stenosis, grade III–IV spondylolisthesis, or prior lumbar surgery were excluded.

  • 4

    All procedures were performed by one senior spinal surgeon using an endoscopic approach for decompression, bone grafting, and interbody fusion.

  • 5

    Expandable cages were described as insertable at low volume and expandable in situ, whereas static PEEK cages have fixed dimensions.

Original Source(s)

Comparison of the short-term efficacy of percutaneous endoscopic transforaminal lumbar interbody fusion with the application of a expandable versus PEEK cage for the treatment of lumbar degenerative disease

  • by Hao Han, Qi Lu, Yu Kong, Yiming Li, Weiqing Kong, Jie Li, Long Yang, Guangchao Cao

  • October 8, 2026

Related Content

AI Scribes Lag Clinicians on Note Quality

A VHA study across 11 vendors finds AI-generated primary care notes score lower than clinician-written notes, with the largest deficits in thoroughness, organization, and usefulness

Acute bilateral foot drop with or without cauda equina syndrome—a case series

FDA Clears Olastrocel Trial Expansion

Additional patients with ongoing opioid use are being enrolled as Creative Medical prepares for potential Phase 3 discussions with the FDA.